Cancer
Malignant Central Nervous System Neoplasm
CI-CAN-00001115Explore in graph →
Top-level822 active trials5 approved drugs103 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001115Explore in graph →
Clinical trials
2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (418)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04221503 | Niraparib/TTFields in GBM | active not recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT02870907 |
| Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)(RB SFCE 09) |
| active not recruiting |
| Phase 2 |
| 195 |
| Institut CurieOTHER |
| 1 |
| Jan 7, 2026 |
| clinicaltrials |
| NCT03743662 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04959500 | Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04116411 | A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients(VIGAS2) | active not recruiting | Phase 2 | 220 | Cecilia Soderberg-NauclerOTHER | 2 | Dec 22, 2025 | clinicaltrials |
| NCT04691960 | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | active not recruiting | Phase 2 | 18 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | recruiting | Phase 1 / Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05554302 | Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis(CONCORDANT) | recruiting | Phase 2 | 20 | Baptist Health South FloridaOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome(RETINO 2018) | recruiting | Phase 2 / Phase 3 | 225 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02866136 | Conservative Treatments of Retinoblastoma(RETINO2011) | active not recruiting | Phase 2 | 133 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03718767 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | active not recruiting | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04945148 | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide(OPTIMUM) | recruiting | Phase 2 | 640 | Hopital FochOTHER | 2 | Nov 21, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT01878617 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | active not recruiting | Phase 2 | 660 | St. Jude Children's Research HospitalOTHER | 4 | Nov 13, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04373785 | NG101m Adjuvant Therapy in Glioblastoma Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | NeuGATE TheranosticsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT06059690 | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | recruiting | Phase 1 / Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT05734560 | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | recruiting | Phase 1 / Phase 2 | 50 | Darell BignerOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07193654 | Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06835803 | Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial(ELITE-GBM) | recruiting | Phase 2 | 56 | Brigham and Women's HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05698147 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | recruiting | Phase 1 / Phase 2 | 30 | Tong Chen, MDOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06102525 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | recruiting | Phase 1 / Phase 2 | 43 | Rznomics, Inc.OTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04863950 | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | recruiting | Phase 2 | 25 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04587830 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme(GBM) | active not recruiting | Phase 2 | 100 | Polaris GroupINDUSTRY | 2 | Aug 26, 2025 | clinicaltrials |
| NCT07138001 | Phase 2 Clinical Trial of KH617 | not yet recruiting | Phase 2 | 60 | Sichuan Honghe Biotechnology Co., Ltd.INDUSTRY | 0 | Aug 22, 2025 | clinicaltrials |
| NCT04747145 | Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma | active not recruiting | Phase 2 | 38 | Medical College of WisconsinOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130149 | Sonodynamic-Chemoradiotherapy Integration in Glioblastoma | enrolling by invitation | Phase 2 | 230 | Yingjuan ZhengOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06356883 | Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma | recruiting | Phase 2 | 120 | Université de SherbrookeOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT04961515 | Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 19 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04175301 | Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. | active not recruiting | Phase 2 | 15 | Stony Brook UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05929495 | Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma | recruiting | Phase 2 | 25 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04523688 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma(Combi G-Vax) | recruiting | Phase 2 | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07047066 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Tongji HospitalOTHER | 0 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT02780024 | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM | active not recruiting | Phase 2 | 50 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04765098 | Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | recruiting | Phase 2 | 60 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04121455 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients(GLORIA) | active not recruiting | Phase 1 / Phase 2 | 117 | TME Pharma AGINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 8, 2026source: clinicaltrials